Moderators: docj
Search This Board: 
Created: 09/27/2009 04:11:41 PM - Followers: 123 - Board type: Free - Posts Today: 0


https://genebiotherapeutics.com/

For filings:https://genebiotherapeutics.com/investors/


Investment by Nostrum Pharmaceuticals LLC: https://www.otcmarkets.com/filing/html?id=14182106&guid=TmVFUWUD04P0tth

On August 2, 2021, the Audit Committee approved the appointment of RAM Associates, LLP (“RAM Associates”) as our new independent registered public accounting firm, effective immediately, to perform independent audit services for the fiscal years ending December 31, 2021 and 2020. RAM Associates has served as the auditor for Nostrum Laboratories, Inc. and its affiliates, which are subsidiaries of Nostrum Pharmaceuticals LLC, our largest shareholder, since 2008.


Clinicaltrials.com update:
https://clinicaltrials.gov/ct2/show/NCT02928094?term=generx&rank=1


Understanding refractory angina and the AFFIRM study:
https://www.myrefractoryangina.com/




Taxus Cardium Announces Name Change To Gene Biotherapeutics

January 10, 2018PR-M01-18-NI-021

SAN DIEGO, Jan. 8, 2018 /PRNewswire/— Taxus Cardium Pharmaceuticals Group (Trading Symbol: CRXM) today announced plans to affect a name change from Taxus Cardium Pharmaceuticals Group Inc. to Gene Biotherapeutics Inc. 

The name change reflects the Company's plan to exclusively focus on the late-stage clinical research and commercialization of gene-based biotherapeutics for niche markets in the oncology and cardiology spaces for patients with unmet medical needs.  Gene Biotherapeutics is actively pursuing the acquisition of clinical development and commercialization rights to new and innovative, late-stage, DNA-based product opportunities focused on multiple forms of cancer to leverage the company's established and validated adenovector-based technology platform and deep experience in the clinical advancement and commercialization of gene therapy product candidates.

Previously, the Company established Angionetics Inc., an 85% majority-owned subsidiary, to lead Gene Biotherapeutics' cardiovascular clinical research and commercialization activities.  Angionetics is currently focused on independent financings to support advancement of the FDA-cleared, Generx AFFIRM Phase 3 clinical study of patients with refractory angina (myocardial ischemia) due to advanced coronary artery disease. There are an estimated 1.0 million patients with refractory angina in the United States. Gene Biotherapeutics' plan to advance forward to establish Angionetics as an independent company remains unchanged.  As previously reported, Gene Biotherapeutics expects to retain a substantial long-term equity investment in Angionetics following completion of the planned external financings. For more information about the Generx AFFIRM Phase 3 clinical study visit www.MyRefractoryAngina.com.

Angionetics is also considering the initiation of multiple Phase 2 clinical studies to evaluate the Generx angiogenic gene therapy product candidate as a treatment for patients with Cardiac Syndrome X (microvascular dysfunction) and certain forms of congestive heart failure, including ischemic cardiomyopathy.

Angionetics' Generx [Ad5FGF-4] is a first in class, disease altering, one-time administered, late-stage, angiogenic gene therapy product candidate which has been biologically engineered to enhance blood flow (perfusion) in ischemic regions of the heart by leveraging cardiac plasticity to promote the natural formation and growth of microvascular coronary structures (collateral vessels). This is achieved by stimulating and augmenting the heart's innate natural capacity to modulate the enlargement of pre-existing collateral arterioles (arteriogenesis), and to form new capillary vessels (angiogenesis) in select ischemic regions downstream from large coronary arteries.

Angionetics is being uniquely positioned to become a leading molecular interventional cardiology company, and is seeking to develop a portfolio of new and innovative, single-treatment, gene-based, catheter-administered therapeutic products focused on the biologic modulation of cardiac conductivity, contraction and angiogenic revascularization to address the global unmet medical needs of millions of patients with multiple forms of heart disease. Consistent with Angionetics' business strategy, the company is currently considering the acquisition of several early-stage gene therapy product candidates.  To learn more about Angionetics visit www.angionetics.com.

As previously reported, Gene Biotherapeutics further plans to monetize its FDA-cleared, U.S.-patented, Excellagen, a highly-purified, aseptically-manufactured, fibrillar bovine collagen [2.6%] flowable dermal matrix for the treatment of diabetic neuropathic lower extremity ulcers, pressure and venous ulcers as well as other wound healing applications.  Excellagen has demonstrated its medical utility as a delivery platform for stem cells, and also carries the potential as a topical dermal delivery vehicle for small molecule drugs, peptides, proteins, and exosomes.   Excellagen® has been designated as a skin substitute (bearing a unique product Q Code), in accordance with the standards established by the U.S. Centers for Medicare and Medicaid Services (CMS). For more information about Excellagen, visit https://www.youtube.com/watch?v=D2GYCYc_8JE.

As of December 31, 2017, approximately 14.3 million shares of Gene Biotherapeutics Common Stock were issued and outstanding, and approximately 4.6 million additional shares of Common Stock have been reserved for future issuance upon the conversion of the Series A Convertible Preferred Stock.

 
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
PlusOneCoin Top Posts Free PlusOneCoin
No plusone'd posts yet. Be the first!
Post Subject
#5775
He is. My acquaintance talked to him on _fatty_ 06/22/2022 06:30:05 PM
#5774
I agree. Doesn't mean I like the way docj 06/22/2022 06:50:45 AM
#5773
IMO This will fly once current with or JJ24 06/21/2022 07:55:35 PM
#5772
Not suggesting they don't intend to get current. docj 06/21/2022 07:33:51 PM
#5771
Well they have never said they not going JJ24 06/21/2022 07:08:34 PM
#5770
Is C. Reinhard even still alive?! BlueChip$ 06/21/2022 06:50:49 PM
#5769
I'm sure you are not alone. docj 06/21/2022 05:40:09 PM
#5768
In my top 5 worst investment ever here, vinsterr 06/16/2022 01:35:49 PM
#5766
docj.....I Believe We Will See A Flurry Of bentleyt 06/15/2022 10:40:04 AM
#5765
Due for news or at least another filing. docj 06/15/2022 06:54:48 AM
#5764
Yup, new cost basis. campe 06/10/2022 01:34:35 PM
#5763
Anyone knows what happens if you do total _fatty_ 06/10/2022 11:56:58 AM
#5762
There are certainly reasons for this lack of marketmanallm 06/02/2022 02:16:26 PM
#5761
No doubt! The point that this stalling as BlackSnake1 05/27/2022 08:48:02 PM
#5760
On the bright side the domain seems to _fatty_ 05/27/2022 08:23:22 AM
#5759
Problem is at the rate they are completing docj 05/27/2022 06:50:06 AM
#5758
I’m always surprised to see new posts on crazyflavor 05/26/2022 10:08:19 PM
#5757
Altitrade.....Any Thoughts.....Ideas.....Updates....We Respect Your Knowledge An bentleyt 05/26/2022 04:53:17 PM
#5756
marketmanallm.....I Can Understand Your Logic....I Still Expect That bentleyt 05/26/2022 12:09:49 PM
#5755
Anyone remembers the days our 2 heroes here _fatty_ 05/25/2022 04:35:31 PM
#5754
We can only go up from here! Lol! JJ24 05/25/2022 12:03:34 PM
#5753
I believe Metformin is a large portion of marketmanallm 05/25/2022 11:54:47 AM
#5752
Nostrum was not alone in the Metformin recall......Apotex,Amneal,Lupins,Marksans bentleyt 05/25/2022 11:26:01 AM
#5750
If you do some digging you will find marketmanallm 05/25/2022 09:57:38 AM
#5749
Good to hear (if true), but....filings not current BlueChip$ 05/25/2022 08:34:27 AM
#5748
There are shareholders who are in communication with docj 05/25/2022 08:20:18 AM
#5747
Faith is a God thing, not a stock BlueChip$ 05/24/2022 08:26:42 PM
#5746
Bluechip.....I Expect The Completed Filings.....A P.R. Regarding OTCQB bentleyt 05/24/2022 06:51:48 PM
#5745
Are they even still in business? Seems like BlueChip$ 05/24/2022 05:09:32 PM
#5744
When are these people running the show going BlackSnake1 05/24/2022 03:44:28 PM
#5743
Look at what happened to Andrew Cuomo.....In this bentleyt 05/24/2022 11:00:00 AM
#5742
Sounds like this guy would be a great campe 05/20/2022 12:53:38 PM
#5741
Been cutting down on beer to save the _fatty_ 05/20/2022 10:05:16 AM
#5740
I would not hold my breath. They have lakes 05/20/2022 06:14:52 AM
#5739
Super pathetic that a company that has assets BlackSnake1 05/19/2022 03:21:56 PM
#5737
When not trading and zero real news, I BlackSnake1 05/06/2022 05:10:24 PM
#5736
docj.....For Sure We Need To See The Complete Picture bentleyt 05/06/2022 11:55:53 AM
#5735
Seems to me the subsequent quarter filings from docj 05/06/2022 07:52:53 AM
#5734
My sense is they may have the quarters marketmanallm 05/06/2022 07:49:06 AM
#5733
Totally inexcusable not to have this ticker trading BlackSnake1 05/05/2022 04:24:42 PM
#5732
docj.....All in the works....IMHO SOON bentleyt 05/03/2022 11:38:20 PM
#5731
It would be nice to get notice a docj 05/02/2022 07:03:37 PM
#5730
One good thing about this ticker is its _fatty_ 04/29/2022 03:45:09 PM
#5729
How is this relevant in 2022? Tia, campe 04/27/2022 02:42:19 PM
#5728
$CRXM: This is now ANGIONETICS ???? makinezmoney 04/27/2022 11:22:06 AM
#5727
docj....thanks! bentleyt 04/19/2022 04:06:43 PM
#5726
EXPLANATORY NOTE TO 10-K/A docj 04/19/2022 10:37:32 AM
#5725
docj.....What was the 10-K amendment about? bentleyt 04/19/2022 10:10:50 AM
#5724
"We intend to become current" ..I believe marketmanallm 04/15/2022 04:05:49 PM
#5723
One of my biggest loser here, I still vinsterr 04/14/2022 11:36:32 AM
Post Subject